Interactive radio’s promising role in climate information services: Farm Radio International concept paper

This paper focuses on how interactive radio programming can increase the reach of weather and seasonal climate information and related advisory services. In doing so, they can enhance small-scale farmers’ capacity to make optimal decisions and manage risks based on a better understanding of probabilistic seasonal forecasts. The objective is to outline strategy that could vastly and affordably expand the number of small-scale farmers that are reached by and benefit from weather and climate information and related advisory services. Building on Farm Radio International’s (FRI) pioneering African Farm Radio Research Initiative (AFRRI), we assess the opportunities for interactive radio to provide integrated climate and advisory information while increasing farmers’ equitable access to salient and legitimate programming. We describe a number of practical strategies that can be used to make radio-based climate communication interactive, outline elements of a successful interactive radio service targeting rural communities, and discuss costs and other issues required for sustainability

BurstCube: A CubeSat for Gravitational Wave Counterparts

BurstCube will detect long GRBs, attributed to the collapse of massive stars, short GRBs (sGRBs), resulting from binary neutron star mergers, as well as other gamma-ray transients in the energy range 10-1000 keV. sGRBs are of particular interest because they are predicted to be the counterparts of gravitational wave (GW) sources soon to be detectable by LIGO/Virgo. BurstCube contains 4 CsI scintillators coupled with arrays of compact low-power Silicon photomultipliers (SiPMs) on a 6U Dellingr bus, a flagship modular platform that is easily modifiable for a variety of 6U CubeSat architectures. BurstCube will complement existing facilities such as Swift and Fermi in the short term, and provide a means for GRB detection, localization, and characterization in the interim time before the next generation future gamma-ray mission flies, as well as space-qualify SiPMs and test technologies for future use on larger gamma-ray missions. The ultimate configuration of BurstCube is to have a set of $\sim10$ BurstCubes to provide all-sky coverage to GRBs for substantially lower cost than a full-scale mission.Comment: In the 35th International Cosmic Ray Conference, Busan, Kore

Delivering climate services for farmers and pastoralists through interactive radio

A scoping study to assess demand, opportunities and potential for the use of interactive radio to deliver climate services at scale for farmers and pastoralists was conducted by CCAFS in partnership with Farm Radio International in Tanzania, and Farm Radio Trust in Malawi in late 2014. Over 1280 individuals were interviewed in an audience research activity, while a desk survey, key informant interviews and knowledge partner engagement activities were undertaken to validate audience research and assess the wider context. The study reveals that for both Malawi and Tanzania, there is clear demand for climate information services via radio and mobile phone. Both radio and mobile phones are in common use, and are rated by farmers and pastoralists to have great potential as effective and trusted channels where they can access various climate information services. Surveyed farmers and pastoralists noted that radio programs, backed up by ICT services, would serve them best. Rainfall patterns, temperature data and forecasting services – both weekly and daily – were mentioned as particular needs. In general, farmers would trust climate information received via their preferred radio stations, and would use it in decision-making on their farms. Women and men differed in time spent listening to radio, in mobile phone airtime purchased, and in Malawi, phone ownership; but larger location differences masked any gender differences in preferences about information content, delivery channels, or expectations about user and benefit. As a response to farmer articulated demand, Farm Radio International and Farm Radio Trust propose working with key institutions and radio station partners to develop interactive programming for rural climate services as part of their implementation of the GFCS Adaptation Programme in Africa. Interactive climate services radio programming would respond to farmers’ ongoing climate information needs, and will engage them in program design, broadcast, monitoring and evaluation – together with partner radio stations. Interactive climate services radio programming will consist of short weekly radio programs, with the option of daily forecasts or interpretations, and will be complemented with ICT services via mobile phone. Programs will be continuously monitored and assessed by audiences and project staff to ensure relevance, usefulness, level of use and accuracy

BurstCube: A CubeSat for gravitational wave counterparts

BurstCube aims to expand sky coverage in order to detect, localize, and rapidly disseminate information about gamma-ray bursts (GRBs). BurstCube is a\u276U\u27 CubeSat with an instrument comprised of 4 Cesium Iodide (CsI) scintillators coupled to arrays of Silicon photo-multipliers (SiPMs) and will be sensitive to gamma-rays between 50 keV and 1 MeV. BurstCube will assist current observatories, such as Swift and Fermi, in the detection of GRBs as well as provide astronomical context to gravitational wave (GW) events detected by LIGO, Virgo, and KAGRA. BurstCube is currently in its development phase with a launch readiness date in early 2022

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy

A LigA Three-Domain Region Protects Hamsters from Lethal Infection by Leptospira interrogans

The leptospiral LigA protein consists of 13 bacterial immunoglobulin-like (Big) domains and is the only purified recombinant subunit vaccine that has been demonstrated to protect against lethal challenge by a clinical isolate of Leptospira interrogans in the hamster model of leptospirosis. We determined the minimum number and location of LigA domains required for immunoprotection. Immunization with domains 11 and 12 was found to be required but insufficient for protection. Inclusion of a third domain, either 10 or 13, was required for 100% survival after intraperitoneal challenge with Leptospira interrogans serovar Copenhageni strain Fiocruz L1-130. As in previous studies, survivors had renal colonization; here, we quantitated the leptospiral burden by qPCR to be 1.2×103 to 8×105 copies of leptospiral DNA per microgram of kidney DNA. Although renal histopathology in survivors revealed tubulointerstitial changes indicating an inflammatory response to the infection, blood chemistry analysis indicated that renal function was normal. These studies define the Big domains of LigA that account for its vaccine efficacy and highlight the need for additional strategies to achieve sterilizing immunity to protect the mammalian host from leptospiral infection and its consequences

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention